MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase

Zhongwei Cao1, Hua Fan-Minogue2, David I. Bellovin1, Aleksey Yevtodiyenko1, Julia Arzeno1, Qiwei Yang1, Sanjiv Sam Gambhir2, and Dean W. Felsher1

Abstract

MYC is a potential target for many cancers but is not amenable to existing pharmacologic approaches. Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) by statins has shown potential efficacy against a number of cancers. Here, we show that inhibition of HMG-CoA reductase by atorvastatin (AT) blocks both MYC phosphorylation and activation, suppressing tumor initiation and growth in vivo in a transgenic model of MYC-induced hepatocellular carcinoma (HCC) as well as in human HCC-derived cell lines. To confirm specificity, we show that the antitumor effects of AT are blocked by cotreatment with the HMG-CoA reductase product mevalonate. Moreover, by using a novel molecular imaging sensor, we confirm that inhibition of HMG-CoA reductase blocks MYC phosphorylation in vivo. Importantly, the introduction of phosphorylation mutants of MYC at Ser62 or Thr58 into tumors blocks their sensitivity to inhibition of HMG-CoA reductase. Finally, we show that inhibition of HMG-CoA reductase suppresses MYC phosphorylation through Rac GTPase. Therefore, HMG-CoA reductase is a critical regulator of MYC phosphorylation, activation, and tumorigenic properties. The inhibition of HMG-CoA reductase may be a useful target for the treatment of MYC-associated HCC as well as other tumors. Cancer Res; 71(6): 2286–97. ©2011 AACR.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common and generally incurable malignancies with an estimated 9% 5-year survival rate (1). Hepatocellular carcinogenesis is strongly associated with hepatitis B and C virus (HBV and HCV) infection and other pathologic conditions resulting in liver regeneration (2), which, in turn, facilitates the activation of specific oncogenes, most notably MYC (c-MYC: 3). Thus, targeted inactivation of MYC may be an effective therapy for HCC (4–6). Indeed, we have reported recently that the conditional inactivation of MYC can be sufficient to induce sustained regression of HCC (7). However, there is no existing therapy that targets MYC for the treatment of any cancer.

The MYC protooncogene family is composed of c-MYC, N-MYC, and L-MYC and has been shown to impact almost every aspect of tumorigenesis, including promoting unrestricted cell proliferation, inhibiting cell differentiation, reducing cell adhesion, and enhancing metastasis, genomic instability, and angiogenesis (8, 9). MYC functions as an oncogene upon overexpression, either due to increased expression of the myc gene or due to increased stability of the MYC protein. MYC protein stability is regulated as follows (10): through the ubiquitin/26S proteasome pathway and the sequential phosphorylation of MYC at serine 62 (S62) and threonine 58 (T58). The phosphorylation of S62 is mediated by the MAPK/ERK (mitogen activated protein kinase/extracellular signal regulated kinase) pathway and contributes to the stabilization of MYC. Subsequent phosphorylation of T58, mediated by GSK3β, promotes ubiquitin-dependent MYC degradation once S62 is dephosphorylated (11–13). Mutations in these phosphorylation sites that stabilize MYC protein have been identified in human cancers, thereby highlighting the importance of S62 and T58 phosphorylation as regulators of MYC in tumorigenesis (14, 15). Hence, targeting MYC phosphorylation could be useful as an anticancer therapy.

The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) controls the rate-limiting step in the mevalonate (MV) pathway that is essential for cholesterol biosynthesis (16). Statins were initially utilized to inhibit HMG-CoA reductase as a means to reduce the serum cholesterol biosynthesis (16). Statins were initially utilized to inhibit HMG-CoA reductase as a means to reduce the serum cholesterol
HMG-CoA reductase also has antitumor efficacy both in vitro and in vivo in multiple tumor types (17–20), including colorectal cancer (21, 22), breast cancer (23), melanoma (24), and lymphoma (25). Statins have been suggested to block tumor cell growth through the inhibition of proliferation and angiogenesis, induction of apoptosis, and repression of tumor metastasis (26).

Statins may mediate their anticancer properties through inhibition of the synthesis of lipid isoprenoid intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are produced downstream of the MV pathway (19). Generally, FPP activates the Ras GTPase family whereas GGPP activates the Rho/Rac family by prenylating and anchoring them on the cell membrane (27). Both Ras (12, 27) and Rho/Rac family members (28) are required to phosphorylate MYC. Hence, we speculated that by inhibiting these pathways, statins might therefore block MYC activation.

Here we show that the inhibition of HMG-CoA reductase by atorvastatin (AT) inhibits MYC phosphorylation and activation and thereby blocks MYC-induced HCC onset and tumor maintenance. Moreover, by using a novel molecular imaging sensor that noninvasively detects MYC phosphorylation, we found, both in vitro in human HCC cells and in vivo in mice, that AT inhibits MYC phosphorylation. Furthermore, the introduction of mutant MYC alleles that cannot be phosphorylated on S62 or T58 prevented AT from inhibiting the in vivo tumor growth of HCC. Finally, we provide evidence suggesting that AT may mediate these effects on MYC phosphorylation and activation by inhibiting Rac GTPase. Therefore, HMG-CoA reductase seems to be a critical regulator of MYC activation and may have potent activity against MYC-induced cancers.

Materials and Methods

Antibodies

The antibody to Ki67 was obtained from BD Biosciences; c-MYC, Cdk4, E2F1, and Rac1 antibodies were obtained from Santa Cruz Biotechnology; phospho-c-MYC was obtained from Cell Signaling Technology; antibodies to Tubulin and HA were from Sigma-Aldrich. Horseradish peroxidase conjugated sheep anti-mouse IgG and sheep anti-rabbit IgG were from Cell Signaling Technology; antibodies to Tubulin and HA were from Abcam. c-MYCS62A (Ad-c-MYCS62A), and c-MYCT58A (Ad-c-MYCT58A) viruses were kindly provided as a gift from Dr. Rosalie C. Sears (Oregon Health & Science University, Portland, OR). Briefly, Ad-c-MYCWT, Ad-c-MYC562A, and Ad-c-MYC758A viruses were cloned by inserting c-MYCWT (Ad-c-MYCWT), c-MYC562A (Ad-c-MYC562A), and c-MYC758A (Ad-c-MYC758A) cDNA into the pADEasy-1 backbone (Stratagene). Transduced SCID mice were injected with hepatocellular carcinoma cell line, and may have potent activity against MYC-induced cancers.

AT treatment

AT (prescription formulation; Pfizer Inc.) was resuspended in PBS. It was administered orally in 100 mg/kg doses with or without 20 mg/kg MV 3 times a week, using 20-mm feeding needles (Popper and Sons). PBS was administered as a negative control. Purified AT (Sequoia Research Products) resuspended in 100% DMSO was used for in vitro studies.

Histology and immunohistochemistry

Tissues were fixed in 10% buffered formalin and embedded in paraffin. Sections of 5 μm were stained with hematoxylin–eosin (H&E) or analyzed by immunohistochemistry using the antibody to Ki67. DAB (3,3’-diaminobenzidine; Vector Laboratories) was used to achieve color development.

Proliferation assay

Cells were seeded in 24-well plates (5,000 cells/well) and incubated overnight. Next, cells were treated with PBS, AT (0.5, 1.0, 2.5, 5.0, 10, or 25 μmol/L), 10 or 25 μmol/L AT and 100 μmol/L MV, 10 or 25 μmol/L AT and 10 μmol/L FPP, or 10 or 25 μmol/L AT and 10 μmol/L GGPP for 96 hours. Cell proliferation was evaluated using the MTT assay. Data were from 6 replicated experiments.

Quantitative real-time PCR

HCC cells were treated with PBS, 20 ng/mL Dox, 10 μmol/L AT, or 10 μmol/L AT and 100 μmol/L MV for 24 hours. Total mRNA from HCC cells was extracted and purified using the RNeasy Mini Kit from Qiagen and quantified by spectrophotometer (Beckman Coulter). cDNA was reverse-transcribed from 2 μg of total mRNA using oligo-d(T) primers. Real-time PCR analysis was done in an ABI PRIZM analyzer (Applied Biosystems).

Cell membrane fractionation and protein isolation

Cells (2 × 10^6) were washed 3 times with PBS and extracted in lysis buffer (50 mmol/L Tris, 50 mmol/L NaCl, 2 mmol/L EDTA, 1 mmol/L MgCl2, 10 mmol/L NaF, 1 mmol/L DTT, pH 7.4). Lysates were centrifuged at 36,000 rpm for 40 minutes, using Beckman L8-70M ultracentrifuge. The membrane pellet was solubilized in immunoprecipitation buffer (0.15 mol/L NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 10 mmol/L Tris-HCl, pH 7.4) and incubated at 4°C for 30 minutes. The solution was centrifuged at 15,000 rpm for 10 minutes, and the supernatant was collected as the membrane protein fraction.

Viral infection

Ad-c-MYCWT, Ad-c-MYC562A, and Ad-c-MYC758A viruses were kindly provided as a gift from Dr. Rosalie C. Sears (Oregon Health & Science University, Portland, OR). Briefly, Ad-c-MYCWT, Ad-c-MYC562A, and Ad-c-MYC758A adenovirus were cloned by inserting c-MYCWT (Ad-c-MYCWT), c-MYC562A (Ad-c-MYC562A), and c-MYC758A (Ad-c-MYC758A) cDNA into the pADEasy-1 backbone (Stratagene). Transplanted tumor cells were infected as previously described (29). Briefly, SCID mice were injected with hepatocellular
carcinoma cells isolated from LAP-tTA/TRE-MYC transgenic mice. Tumor masses were injected at 3 sites with Ad-c-MYC\textsuperscript{WT} or Ad-c-MYC\textsuperscript{TSSD} once every week. Successful infection was confirmed by green fluorescent protein (GFP) coexpression in tumors (Supplementary Information, Fig. S9). Mice were treated with 100 μg/mL Dox to inactivate transgenic MYC expression. Tumor growth was measured using calipers 3 times a week for 3 weeks after viral injection.

**Immunoprecipitation and immunoblotting**

Cells were lysed in immunoprecipitation buffer (0.15 mol/L NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 10 mmol/L Tris-HCl, pH 7.4) and cleared lysates were immunoprecipitated with 2 μg HA antibody. The precipitated proteins were resolved by SDS-PAGE, transferred to nitrocellulose, and blotted with the antibodies indicated in the figures. Total MYC and phospho-MYC level were detected by immunoblotting, and their optical density (OD) was measured and normalized to actin band OD. The MYC phosphorylation level was determined by the ratio between phospho-MYC and total MYC.

**Molecular imaging of MYC phosphorylation**

A bioluminescent sensor system that can noninvasively detect c-MYC phosphorylation was utilized to detect the AT inhibitory effect in intact cells and living mice. The sensor system utilizes the fact that S62 phosphorylation of MYC is required for its interaction with GSK3β and detects the protein interaction between GSK3β and MYC to indirectly report the MYC phosphorylation, using a split Firefly luciferase (FL) complementation system (30). Specific GSK3β and MYC fragments are fused with the inactive C-terminal and N-terminal fragment of the split FL, respectively (GSK35–433-CFL/NFL-c-Myc). Phosphorylation-induced interaction between GSK3β and MYC brings the 2 split fragments into close proximity and recovery of the luciferase activity.

The sensor system has been validated both in intact cells and in mouse xenograft model, which is described in an independent article (31). For in vitro imaging, the sensor plasmids were transiently transfected into HuH7 and HepG2 cells, using Superfect (Qiagen) and Lipofectamine 2000 (Invitrogen) reagent, respectively. Renilla luciferase (RL) gene was cotransfected for the control of the transfection efficiency. Twenty-four hours after transfection, cells were treated with AT with different concentration as indicated for 18 hours. Bioluminescent imaging (BLI) was conducted in IVIS 50 (Caliper Life Science) after adding 45 μg/mL d-Luciferin (Promega) to the cells. Cells were lysed for RL assay (Promega) and Western blotting analysis after imaging. For in vivo liver tumor imaging, we used a hydrodynamic injection method as previously described (32). Briefly, 2 mL of saline solution containing 25 μg of the MYC sensor plasmid with CMV promoter was injected into the tail vein within 8 seconds. Mice were imaged in IVIS 200, 22 hours after injection, based on time course of the sensor expression as determined in control experiments (Supplementary Information, Figs. S6 and S7).

**Results**

**Inhibition of HMG-CoA reductase by AT suppresses MYC-induced HCC**

The effects of inhibition of HMG-CoA reductase were examined on HCC growth in vitro and in vivo by administering AT to multiple HCC tumor cell lines derived from the LAP-tTA/TRE-MYC transgenic mice, a previously described conditional transgenic model of MYC-induced HCC, using the Tet-system (7), in addition to human HCC cell lines. The murine cell lines were all generated from HCC isolated from dual transgenic animals. These cell lines are dependent upon high levels of human MYC expression, which can be inactivated upon treatment with Dox. Hence, in these transgenic tumor-derived cell lines, as a positive control for MYC inactivation, we used Dox to induce the suppression of transgenic MYC. Doses of AT used for our experiments were comparable with previously published studies (33, 34). Moreover, as control for nonspecific effects of statins, we confirmed that effects were reversed with cotreatment with the enzyme product of HMG-CoA reductase MV. Note that because of marked differences in the pharmacokinetics between mouse and human, AT doses in mice are approximately 50-fold higher than the pharmacologically equivalent dose in humans (35, 36).

First, AT inhibited the in vitro proliferation of the MYC-induced murine cell line HCC 3-4 as measured by the MTT assay (Fig. 1A and Supplementary Information, Fig. S2A; 75% decrease at 10 μmol/L and 92% decrease at 25 μmol/L AT at 96 hours of AT treatment, P < 0.0001 each). Also, AT decreased the number of cells in S and G2/M phases from 38% to 26%, as assessed by propidium iodide (PI) staining (Fig. 1B, P = 0.01), and reduced Ki67 immunofluorescence from 81.4% to 31.2% following 48 hours of 10 μmol/L AT treatment (Fig. 1C, P < 0.0001). Importantly, the effects of AT on proliferation and cell-cycle arrest were rescued by cotreatment with MV, the immediate downstream target of HMG-CoA reductase (Fig. 1A–C), confirming these effects are specific to inhibition of the cholesterol biosynthesis pathway. Moreover, AT was found to similarly inhibit proliferation and induce cell-cycle arrest and apoptosis in 2 independently derived murine HCC cell lines, EC4 and HCC 4-4, in a dose-dependent manner (Supplementary Information, Figs. S1–S3). Thus, AT inhibits proliferation and induces apoptosis of murine HCC tumor cells in vitro.

Second, AT inhibited the growth of the murine HCC 3-4 cell line transplanted into syngeneic mice by up to 80% compared with treatment by PBS or AT and MV (Fig. 1D and E, P = 0.0003). Note, that FVB/N mice treated with 100 mg/kg AT did not exhibit any general toxicity and, in particular, had normal liver histology and serum bilirubin levels, showing that the clinical effects are not secondary nonspecific hepatotoxicity (Supplementary Information, Fig. S4). Therefore, inhibition of HMG-CoA reductase by AT has potent in vivo antitumor activity against murine MYC-induced HCC.

Third, we interrogated the ability of AT to suppress growth in HuH7 cells, a human HCC cell line. AT blocked the in vitro growth of HuH7 cells over a 96-hour time course (Fig. 2A and Supplementary Information, Fig. S2B; 69% decrease at 10
μmol/L and 86% decrease at 25 μmol/L AT, \( P < 0.0001 \) each) while inhibiting cell-cycle progression (Fig. 2B; 75% reduction in S phase, \( P = 0.003 \)) and reducing Ki67 positivity (Fig. 2C; 58% reduction, \( P < 0.0001 \)) following 48 hours of 10 μmol/L AT treatment. Moreover, AT suppressed the \( in vivo \) growth of HuH7 cells (Fig. 2D; PBS vs. AT, \( P = 0.03 \); AT vs. AT + MV, \( P = 0.04 \); PBS vs. AT + MV, \( P = 0.8 \)). Cotreatment with MV blocked the effects of statin treatment, confirming that the inhibition of human HCC by AT is specific to the suppression of HMG-CoA reductase (Fig. 2A–D).

Finally, we evaluated the ability of HMG-CoA reductase inhibition to block the initiation of MYC-induced HCC growth \( in vivo \) in the LAP-tTA/TRE-MYC transgenic mice treated with PBS, AT, or AT with MV (Fig. 3A, left). Treatment with 100 mg/kg AT versus PBS significantly delayed tumor onset and increased survival (Fig. 3A; median survival increased from 80 to 147 days, \( P < 0.005 \)). Importantly, MV treatment prevented AT from inhibiting tumorigenesis (Fig. 3A). Gross pathology revealed that AT markedly reduced the size and frequency of tumor nodules (Fig. 3B, left). H&E staining...
revealed histologically normal liver tissue in AT-treated mice, suggesting a robust inhibition of disease onset (Fig. 3B, middle). AT-treated animals also exhibited evidence of inhibited cell proliferation, as indicated by reduced Ki67 staining compared with PBS-treated mice (Fig. 3B, right; 8 ± 3 positive cells vs. 422 ± 23 positive cells per field, \( P < 0.02 \)). Hence, inhibition of HMG-CoA reductase by AT is potent at inhibiting MYC-induced liver tumorigenesis.

**Inhibition of HMG-CoA reductase suppresses MYC phosphorylation, stability, and transactivation**

MYC activation has been shown to be regulated by phosphorylation (12). Thus, we considered that AT might exert its antineoplastic effects by inhibiting MYC phosphorylation. Indeed, AT, but not AT with MV, was found to induce a dose-dependent downregulation of MYC phosphorylation in vitro upon 24 hours treatment (Fig. 4A; 29% reduction at 0.5 \( \mu \text{mol/L} \), 34% at 1.0 \( \mu \text{mol/L} \), 34% at 2.5 \( \mu \text{mol/L} \), 83% at 5.0 \( \mu \text{mol/L} \), 94% at 10 \( \mu \text{mol/L} \), and 97% at 25 \( \mu \text{mol/L} \); \( P = 0.004 \)) as well as in vivo (Fig. 4B; 93% reduction). Moreover, AT blocked MYC phosphorylation in MYC-induced murine lymphoma, osteosarcoma, and lung cancer, as well as in human breast cancer cell lines (data not shown). In turn, the dephosphorylation was associated with a reduction in MYC protein levels in vitro (Fig. 4A; 17% reduction at 0.5 \( \mu \text{mol/L} \), 40% at 1.0 \( \mu \text{mol/L} \), 9% at 2.5 \( \mu \text{mol/L} \), 41% at 5.0 \( \mu \text{mol/L} \), 69% at 10 \( \mu \text{mol/L} \), and 91% at 25 \( \mu \text{mol/L} \); \( P = 0.002 \)) and in vivo (Fig. 4B; 57% reduction, \( P = 0.04 \)). Importantly, the inhibition of MYC phosphorylation by AT not only reduced MYC levels but also seemed to dramatically inhibit MYC transcriptional activation, as illustrated by the reduced mRNA expression of canonical target genes ODC and nucleolin, both in murine (Fig. 4C; 72% reduction for ODC, \( P = 0.0003 \); 76% reduction for nucleolin, \( P = 0.03 \)) and in human HCC upon 24 hours of 10 \( \mu \text{mol/L} \) AT treatment (Fig. 4D; 64% reduction for ODC, \( P = 0.016 \); 59% reduction for nucleolin, \( P = 0.008 \); Supplementary Information, Fig. S8B). Thus, the inhibition of HMG-CoA reductase blocks MYC phosphorylation, reduces MYC protein levels, and inhibits MYC transactivation.

**Noninvasive molecular imaging to measure in vivo MYC phosphorylation**

To evaluate the effects of inhibition of HMG-CoA reductase on MYC phosphorylation in situ in a living host, we utilized a novel molecular imaging sensor system (31). The sensor system consists of 2 parts: (i) a peptide corresponding to the phosphoregulated domain of MYC fused to the N-terminal domain of FL and (ii) the C-terminal domain of FL fused to a peptide fragment of GSK3β that recognizes phospho-MYC (Fig. 5A). When coexpressed in an intact cell, MYC phosphorylation can be detected via interaction between the MYC and GSK3β peptides, thereby localizing the N- and C-termini of FL in close proximity, conferring luciferase activity. RL is cotransfected as a control for transfection efficiency. The full-length FL was also transfected independently into these cells as a control for the direct effect of AT on luciferase activity. We confirmed that this imaging method could detect the dose-dependent...
reduction of MYC phosphorylation in human Huh7 and HepG2 cells upon 18 hours of AT treatment (Fig. 6B and C and Supplementary Information, Fig. S5, $P < 0.0001$).

Next, this imaging sensor was used to monitor MYC phosphorylation in vivo. The sensor system was introduced in liver cells of LAP-tTA/TRE-MYC mice by hydrodynamic injection. Two groups of transgenic mice ($n = 3$ each) had MYC activated at the same time and were treated with either AT or PBS. The MYC sensor was imaged at days 0 and 15 posttreatment. The PBS-treated group showed no significant change of the sensor signal, whereas the AT-treated group showed 72% reduction of the sensor signal at day 15 of treatment (Fig. 5D and E; AT-treated mice day 0 vs. day 15, $P = 0.038$; PBS-treated day 0 vs. day 15, $P = 0.638$). Notably,
AT-mediated inhibition of MYC phosphorylation in vivo was associated with a 44% and 56% downregulation in the expression of downstream target genes, E2F1 and Cdk4 (Supplementary Information, Fig. S8A), further showing the inhibition of MYC activity. Hence, a novel imaging sensor was used to show that the inhibition of HMG-CoA reductase by AT inhibits MYC phosphorylation in vivo.

MYC phosphomutants confer resistance to the inhibition of HMG-CoA reductase

To examine whether inhibition of MYC phosphorylation mediates the anticancer effect of AT, we introduced phosphomutants of MYC into HCC tumor cell lines. First, recombinant adenovirus was used to express MYC that is mutated with either an alanine substitution at either S62 or T58 (Ad-MYC<sub>S62A</sub> and Ad-MYC<sub>T58A</sub>) and hence cannot be regulated by phosphorylation at these sites (37). AT treatment at 10 μmol/L for 24 hours dramatically suppressed WT MYC but failed to significantly inhibit protein levels of either S62A MYC or T58A MYC (Fig. 6A; MYC<sup>WT</sup> vs. MYC<sup>S62A</sup> + AT, P = 0.09; MYC<sup>T58A</sup> vs. MYC<sup>T58A</sup> + AT, P = 0.06). Thus, we concluded that phosphoregulation through either S62 or T58 is necessary for AT to suppress MYC expression.

Using an antibody specific for phospho-S62 and -T58, we show that AT inhibits phosphorylation in T58A MYC similar to wild-type MYC (Fig. 6A, 62% reduction for MYC<sup>WT</sup>, P = 0.01; 68% reduction for MYC<sup>T58A</sup>, P = 0.008). These data show that the reduction of phospho-MYC by AT seems to occur by preventing S62 phosphorylation. However, the reduction of total MYC protein cannot occur without T58 phosphorylation. In addition, HCC cells expressing the S62A MYC mutant were less sensitive whereas cells expressing T58A MYC were completely insensitive to the inhibition of proliferation upon AT treatment (Fig. 6B, 26% reduction for WT, P < 0.001; 17% reduction for S62, P < 0.0001; no reduction for T58, P = 0.8). Thus, inhibition of HMG-CoA reductase suppresses MYC activation in a phosphorylation-dependent manner.

Next, we investigated whether the MYC phosphomutants could suppress the ability of the inhibition of HMG-CoA reductase to block HCC tumor growth in vivo. Syngeneic hosts were transplanted with MYC-induced HCC cells that were then injected with Ad-MYC<sup>WT</sup>, Ad-MYC<sup>S62A</sup>, or Ad-MYC<sup>T58A</sup>. Tumor
Figure 5. A novel bioluminescence c-MYC phosphosensor noninvasively shows AT-dependent inhibition of MYC phosphorylation. A, the N- and C-termini of split FL were fused to the phosphoregulated domain of MYC and the corresponding domain of GSK3β, respectively. Phosphorylation of the MYC peptide results in FL enzymatic activity. B, Huh7 cells were transfected with the MYC phosphorylation sensor and treated with AT. BLI shows a dose-dependent inhibition of phospho-MYC (P < 0.0001). FL activity was normalized to RL activity and plotted against AT concentration. Error bars, SD. C, Western blotting confirms AT-dependent suppression of phospho-MYC in transplanted Huh7 cells. D, LAP-tTA/TRE-MYC transgenic mice were treated with AT or PBS (n = 3), and hydrodynamic injection of the phosphosensor followed by BLI shows AT-dependent inhibition of MYC phosphorylation in vivo (AT-treated mice day 0 vs. day 15, P = 0.038; PBS-treated mice day 0 vs. day 15, P = 0.638). E, FL activity was normalized to RL activity and plotted against days of AT treatment.
target genes, including Cdk4 and E2F1, than FPP following 24 hours of 10 μmol/L AT treatment (Supplementary Information, Fig. S10, 40%–45% reduction for FPP, \( P < 0.001 \); 25%–60% increase for GGPP, \( P < 0.03 \)). MYC phosphorylation was restored to levels similar to PBS-treated controls when media containing 10 μmol/L AT was supplemented with GGPP but not with FPP (Fig. 7C; 76% reduction for FPP, \( P = 0.001 \); 21% reduction for GGPP, \( P = 0.02 \)). Therefore, inhibition of HMG-CoA reductase seems to inactivate MYC through the inhibition of the Rho/Rac pathway.

Finally, we examined the potential role of the Rac/Rho/Cdc42 pathway as a mechanism by which AT suppresses MYC activation. First, we investigated whether AT was influencing the membrane localization of Rac1. Indeed, 24-hour treatment with 10 μmol/L AT resulted in the delocalization of Rac1 from the plasma membrane (Fig. 7D; 83% reduction for AT, \( P < 0.001 \)). As a control, we showed that treatment with MV blocked these effects, as did treatment with GGPP (Fig. 7D; no change for PBS vs. AT + MV; \( P = 0.08 \); 37% increase for PBS vs. GGPP, \( P < 0.03 \)). Notably, AT had little effect on Ras localization (data not shown). Second, using a Rac pull-down assay, 24 hours of 10 μmol/L AT treatment was shown to reduce Rac1 activity by 77% (Fig. 7E). Thus, the inhibition of HMG-CoA reductase by AT seems to suppress activation of the Rac pathway, suggesting that AT in blocks MYC phosphorylation and activation via inhibition of Rac.

**Discussion**

Here, we show that MYC phosphorylation, activation, and thereby tumorigenic potential are regulated by HMG-CoA reductase. In particular, the inhibition of HMG-CoA reductase by statins suppresses MYC phosphorylation and activation. The consequences of these effects on MYC include preventing HCC initiation as well as inhibiting the in vivo growth of established murine and human HCC tumors. Moreover, statins, by blocking HMG-CoA reductase, inhibit GTPase activity, thereby resulting in MYC dephosphorylation and inactivation, which is essential for their anticancer therapeutic effect (Fig. 7F). Hence, the inhibition of HMG-CoA reductase by AT may be an effective strategy for the inhibition of MYC in the treatment and prevention of HCC.

Importantly, we confirmed the antitumor effects of statins that we observed both in vitro and in vivo were specific to HMG-CoA reductase because they could be readily reversed by cotreatment with MV. We note that the AT doses we used in...
mice seem to be higher than generally used in humans. However, it is well known that, because of differences in the pharmacokinetics, murine doses have to be 50-fold higher than in humans (35, 36). Moreover, we confirmed that the antitumor dose of AT did not exhibit toxicity (Supplementary Information, Fig. S4) and hence is likely to be achievable in humans.

The inhibition of HMG-CoA reductase was found to block MYC phosphorylation. First, AT treatment blocks MYC phosphorylation in murine and human HCC cells both in vitro and in vivo. Concomitant treatment with MV abrogates the ability of AT to block MYC phosphorylation and activation and mediate its suppressive effect on HCC growth, indicating that the antineoplastic effect of AT is via the inhibition of HMG-CoA reductase (Fig. 4). Second, a novel phosphorylation sensor was used to show in situ in human HCC cells and in vivo in living mice (Fig. 5). This phosphosensor may be a useful approach to develop therapies that target MYC phosphorylation. Third, mutations in 2 MYC phosphorylation sites, specifically S62 and T58, blocks the ability of AT to inhibit tumor growth in vivo. Therefore, HMG-CoA reductase activity is important to the regulation of MYC phosphorylation. We infer that MYC phosphorylation is an essential component of the mechanism by which statins mediate their antineoplastic properties. The introduction of mutant MYC alleles in HCC tumor cells reduced their sensitivity to statins in vitro and in vivo. Specifically, the differential ability of S62A and T58A MYC to block the effect of AT in vitro and in vivo (Fig. 6)
suggested that AT-mediated reduction in phospho-S62 would therefore result in MYC phosphorylated at only T58, which is rapidly degraded in a ubiquitin-dependent manner (12, 13). Our results are consistent with a role of S62 and T58 phosphorylation in MYC stability and transcriptional activity and, most important, their role in tumorigenesis (12). However, we note that S62/T58 phosphorylation has not always been found to regulate MYC stability (40). We conclude that the inhibition of MYC phosphorylation may be important to the mechanism by which the inhibition of HMG-CoA reductase by statins exerts its antineoplastic properties.

Many reports suggest that statins have antineoplastic properties (25, 41–44). Many mechanisms have been proposed including the inhibition of the ErbB2 pathway (45), the blocking of the interaction between the lymphocyte function–associated antigen and intercellular cell adhesion molecule-1 (46), the suppression of geranylgeranylation of the Rho family proteins (47), and the prevention of the prenylation of RhoA and downstream activation of focal adhesion kinase, AKT, and β-catenin (23). Although we cannot preclude any of these possibilities, our results are consistent with the notion that the inhibition of HMG-CoA reductase by AT in HCC cells blocks MYC phosphorylation likely through the inhibition of small GTPases in the Rac pathway (Fig. 7).

Our results are the first to suggest that HMG-CoA reductase regulates MYC activation via Rac. We are currently investigating the signaling intermediates that may function between Rac and MYC to mediate the antineoplastic effect of AT. Previously, it has been suggested that Rac regulates MYC (28). Rac1 can inhibit protein phosphatase PP2A (48), which has been shown to dephosphorylate MYC at S62 (13). One possible mechanism suggested by our work is that AT inhibition of Rac can result in activation of PP2A, which subsequently dephosphorylates MYC at S62 and induces the ubiquitin-dependent degradation of T58-phosphorylated MYC (Fig. 7F).

Our results illustrate that the inhibition of HMG-CoA reductase by statins may be useful in the treatment and prevention of human HCC. HCC is increasing in incidence, has a generally dismal prognosis, and there are few treatment options (49). Statins were developed to inhibit HMG-CoA reductase in the liver to reduce cholesterol. Hence, they may be aptly suited for treating cancers of the liver. Moreover, statins are well tolerated in humans and may be useful in the prevention of HCC in patients at high risk (49). Notably, some clinical studies have suggested that the statin pravastatin may have clinical activity in patients with HCC (50, 51), whereas other studies have not found clinical benefit (52). A possible explanation for this possible discrepancy in the benefit from statins is that clinical activity could depend upon the activation status of MYC. Also, AT may be a more effective statin for the treatment of HCC.

We conclude that MYC phosphorylation is a critical mechanism by which the inhibition of HMG-CoA reductase by statins mediates their antineoplastic effects. We have shown that a novel molecular imaging sensor may be useful for the identification through high-throughput methods of new therapeutic agents that inhibit MYC phosphorylation and activation. Importantly, statins may be effective agents to inhibit MYC function as a treatment for HCC.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We dedicate this article in memory of Julie Do. We thank Dr. Rosalie C. Sears (Oregon Health & Science University, Portland, OR) for kindly providing us with mutant MYC constructs. We also value the helpful comments provided by Dr. Stacey Adam and the members of the Felsher, Sylvester, and Gambhir laboratories.

Grant Support

This work was supported by NIH grants CA89305-01A1, CA89305-0351, CA105192, and CA112973; Department of Defense grant PR080163; the Burroughs Wellcome Fund; the Leukemia and Lymphoma Society; the Damon Runyon Foundation (D.W. Felsher); and the in vivo cancer molecular image center (KMIC P50) at Stanford grant CA14747 (S.S. Gambhir, D.W. Felsher). Z. Cao was supported by an American Liver Foundation fellowship. H. Minogue is supported by an NIH R25 training grant. D.I. Bellovin is supported by the NIH under NIBSA fellowship F32-CA132312.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 15, 2010; revised January 2, 2011; accepted January 5, 2011; published OnlineFirst January 24, 2011.
MYC Activity Is Regulated by HMG-CoA Reductase


